Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 365-385 , September 2006

Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system

  • Ayalew Tefferi, MD (Professor of Hematology and Medicine, Consultant)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Tel.: +1 507 284 3159; Fax: +1 507 266 4972.

References 

  1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–375
  2. Dameshek W. Foreword and a proposal for considering paroxysmal nocturnal hemoglobinuria (PNH) as a ‘candidate’ myeloproliferative disorder. Blood. 1969;33:263–264
  3. Oni SB, Osunkoya BO, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood. 1970;36:145–152
  4. Ohashi H, Hotta T, Ichikawa A, et al. Peripheral blood cells are predominantly chimeric of affected and normal cells in patients with paroxysmal nocturnal hemoglobinuria: simultaneous investigation on clonality and expression of glycophosphatidylinositol-anchored proteins. Blood. 1994;83:853–859
  5. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711
  6. Parker CJ. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells. 1996;14:396–411
  7. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British cooperative leukaemia group. British Journal of Haematology. 1994;87:746–754
  8. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French–American–British to World Health Organization: a commentary. Blood. 2002;99:3074–3075
  9. Fialkow PJ, Gartler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proceedings of the National Academy of Sciences of the USA. 1967;58:1468–1471
  10. Barr RD, Fialkow PJ. Clonal origin of chronic myelocytic leukemia. The New England Journal of Medicine. 1973;289:307–309
  11. Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. The New England Journal of Medicine. 1976;295:913–916
  12. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. The American Journal of Medicine. 1977;63:125–130
  13. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN. Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. The Journal of Clinical Investigation. 1978;62:815–823
  14. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189–194
  15. Martin PJ, Najfeld V, Hansen JA, et al. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature. 1980;287:49–50
  16. Fialkow PJ, Faguet GB, Jacobson RJ, et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916–919
  17. Gilliland DG, Blanchard KL, Levy J, et al. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proceedings of the National Academy of Sciences of the USA. 1991;88:6848–6852
  18. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981–1983
  19. Tefferi A, Thibodeau SN, Solberg LA. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood. 1990;75:1770–1773
  20. Fugazza G, Bruzzone R, Dejana AM, et al. Cytogenetic clonality in chronic myelomonocytic leukemia studied with fluorescence in situ hybridization. Leukemia. 1995;9:109–114
  21. Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13:32–37
  22. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leukemia Research. 2003;27:883–885
  23. Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c- kit gene. Blood. 2002;100:661–665
  24. Froberg MK, Brunning RD, Dorion P, et al. Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. Leukemia. 1998;12:623–626
  25. Pardanani AD, Morice WG, Hoyer JD, Tefferi A. Chronic basophilic leukemia: a distinict clinico-pathologic entity?. European Journal of Haematology. 2003;71:18–22
  26. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. British Journal of Haematology. 2003;122:173–179
  27. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Journal of the National Cancer Institute. 1960;25:85
  28. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. The New England Journal of Medicine. 2003;348:1201–1214
  29. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365:1054–1061
  30. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature; in press.
  31. Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. The New England Journal of Medicine. 2005;352:1779–1790
  32. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  33. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. The Journal of Biological Chemistry. 2004;
  34. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘Atypical’ myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005. Blood first edition paper, prepublished online April 28, 2005; DOI: 10.1182/blood-2005-03-1183.
  35. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005. Blood first edition paper, prepublished online May 26, 2005; DOI: 10.1182/blood-2005-03-1320.
  36. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. WHO classification of tumors: tumors of the hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001;
  37. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  38. Rosati S, Anastasi J, Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Seminars in Hematology. 1996;33:111–126
  39. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. The New England Journal of Medicine. 2005;352:549–557
  40. Janssen JW, Buschle M, Layton M, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 1989;73:248–254
  41. Jaju RJ, Jones M, Boultwood J, et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q-syndrome. Genes, Chromosomes & Cancer. 2000;29:276–280
  42. Pfeilstocker M, Reisner R, Nosslinger T, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. British Journal of Haematology. 1999;106:455–463
  43. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18:113–119
  44. Lai JL, Preudhomme C, Zandecki M, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia. 1995;9:370–381
  45. Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q-syndrome. Genes, Chromosomes & Cancer. 1998;22:251–256
  46. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood. 2002;99:4638–4641
  47. Bench AJ, Nacheva EP, Hood TL, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene. 2000;19:3902–3913
  48. Virchow R. Weisses blut. Froiep's Notzien. 1845;36:151
  49. Tefferi A, Schad CR, Pruthi RK, et al. Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. Cancer Genetics and Cytogenetics. 1995;83:61–64
  50. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293
  51. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765–767
  52. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–99
  53. Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985;315:758–761
  54. Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. The New England Journal of Medicine. 1985;313:1429–1433
  55. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212–214
  56. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–1082
  57. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proceedings of the National Academy of Sciences of the USA. 1990;87:6649–6653
  58. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824–830
  59. Pendergast AM, Muller AJ, Havlik MH, et al. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161–171
  60. Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene. 1996;12:839–846
  61. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proceedings of the National Academy of Sciences of the USA. 1987;84:6558–6562
  62. Voncken JW, Kaartinen V, Pattengale PK, et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 1995;86:4603–4611
  63. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Research. 1996;56:100–104
  64. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. 1996;2:561–566
  65. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938–1942
  66. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399–401
  67. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141
  68. Clarkson B, Strife A, Wisniewski D, et al. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia. 2003;17:1211–1262
  69. Wilson MB, Schreiner SJ, Choi HJ, et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene. 2002;21:8075–8088
  70. Raskind WH, Jacobson R, Murphy S, et al. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. The Journal of Clinical Investigation. 1985;75:1388–1390
  71. Anger B, Janssen JW, Schrezenmeier H, et al. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia. 1990;4:258–261
  72. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. British Journal of Haematology. 1994;86:253–258
  73. el Kassar N, Hetet G, Li Y, et al. Clonal analysis of haemopoietic cells in essential thrombocythaemia. British Journal of Haematology. 1995;90:131–137
  74. Elkassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia—Advantages of studying T lymphocytes and platelets. Blood. 1997;89:128–134
  75. Shih LY, Lin TL, Dunn P, et al. Clonality analysis using X-chromosome inactivation patterns by HUMARA- PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan. Experimental Hematology. 2001;29:202–208
  76. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417–424
  77. Chiusolo P, La Barbera EO, Laurenti L, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Experimental Hematology. 2001;29:670–676
  78. Bacher U, Haferlach T, Kern W, et al. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Annals of Hematology. 2005;
  79. Sessarego M, Defferrari R, Dejana AM, et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genetics and Cytogenetics. 1989;43:57–65
  80. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematologica. 2002;108:55–65
  81. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Reviews. 2001;15:121–131
  82. Ash RC, Detrick RA, Zanjani ED. In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera. Direct evidence of stem cell involvement. The Journal of Clinical Investigation. 1982;69:1112–1118
  83. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology. 2002;30:229–236
  84. Beckman B, Anderson WF, Beltran G, et al. Mixed myeloid-lymphoid colonies in a patient with polycythemia vera. American Journal of Hematology. 1982;12:419–423
  85. Price CM, Kanfer EJ, Colman SM, et al. Simultaneous genotypic and immunophenotypic analysis of interphase cells using dual-color fluorescence: a demonstration of lineage involvement in polycythemia vera. Blood. 1992;80:1033–1038
  86. Zamora L, Espinet B, Florensa L, et al. Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. Cancer Genetics and Cytogenetics. 2004;151:139–145
  87. Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. British Journal of Haematology. 2002;119:558–566
  88. Gribble SM, Reid AG, Bench AJ, et al. Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH. Leukemia. 2003;17:1419–1421
  89. Chen Z, Notohamiprodjo M, Guan XY, et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes, Chromosomes & Cancer. 1998;22:321–324
  90. Westwood NB, Gruszka-Westwood AM, Atkinson S, Pearson TC. Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization. Haematologica. 2001;86:464–469
  91. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003;102:1869–1871
  92. Pellagatti A, Vetrie D, Langford CF, et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Research. 2003;63:3940–3944
  93. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102:3793–3796
  94. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings. 2003;78:174–194
  95. Engel W, Merker H, Schneider G, Wolf U. Clonal occurrence of a chromosome Dq–in myelosclerosis with myeloid metaplasia. Humangenetik. 1968;6:335–337
  96. Kahn A, Bernard JF, Cottreau D, et al. Gd (–) Abrami: a deficient G-6PD variant with hemizygous expression in blood cells of a woman with primary myelofibrosis. Humangenetik. 1975;30:41–46
  97. Kreipe H, Jaquet K, Felgner J, et al. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood. 1991;78:1814–1817
  98. Ruutu T, Partanen S, Knuutila S. Clonal karyotype abnormalities in erythroid and granulocyte–monocyte precursors in polycythaemia vera and myelofibrosis. Scandinavian Journal of Haematology. 1983;31:253–256
  99. Sugiyama H, Ichiba S, Okuno Y, et al. Cytogenetic evidence for a clonal disorder involving CFU-GEMM, BFU-E and CFU-C in patients with myeloproliferative disorders. Nippon Ketsueki Gakkai Zasshi Acta Haematologica Japonica. 1989;52:1022–1032
  100. Greenberg BR, Woo L, Veomett IC, et al. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. British Journal of Haematology. 1987;66:487–490
  101. Wang JC, Lang HD, Lichter S, et al. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. British Journal of Haematology. 1992;80:184–188
  102. Buschle M, Janssen JW, Drexler H, et al. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988;2:658–660
  103. Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 2001;113:763–771
  104. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. British Journal of Haematology. 1997;98:96–102
  105. Tefferi A. Myelofibrosis with myeloid metaplasia. The New England Journal of Medicine. 2000;342:1255–1265
  106. Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clinic Proceedings. 2005;80:75–83
  107. Sanada I, Asou N, Kojima S, et al. Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia. Report of an additional case. Cancer Genetics and Cytogenetics. 1989;43:139–141
  108. Blatt PM, Rothstein G, Miller HL, Cathey WJ. Loffler's endomyocardial fibrosis with eosinophilia in association with acute lymphoblastic leukemia. Blood. 1974;44:489–493
  109. Keung YK, Beaty M, Steward W, et al. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genetics and Cytogenetics. 2002;138:139–142
  110. Kuroda J, Kimura S, Akaogi T, et al. Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration. Acta Haematologica. 2000;104:119–123
  111. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102:4187–4190
  112. Ma SK, Kwong YL, Shek TW, et al. The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Human Pathology. 1999;30:864–868
  113. Yam LT, Yam CF, Li CY. Eosinophilia in systemic mastocytosis. American Journal of Clinical Pathology. 1980;73:48–54
  114. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. American Journal of Hematology. 2004;77:82–85
  115. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. British Journal of Haematology. 2003;121:203–223
  116. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood. 2003;102:3093–3096
  117. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. The New England Journal of Medicine. 2002;347:481–487
  118. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 2002;16:1207–1212
  119. Trempat P, Villalva C, Laurent G, et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. Oncogene. 2003;22:5702–5706
  120. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics. 2002;11:1391–1397
  121. Safley AM, Sebastian S, Collins TS, et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes, Chromosomes & Cancer. 2004;40:44–50
  122. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459–469
  123. Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences of the USA. 2003;100:7830–7835
  124. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038–3045
  125. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18:734–742
  126. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473–478
  127. Pardanani A, Brockman SR, Li C-Y, et al. FIP1L1-PDGFRA fusion in eosinophilia-associated disorders: prevalence and clinicopathologic correlates. Blood. 2003;102:146a;[Abstract#503]
  128. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307–316
  129. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91:4419–4426
  130. Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 2001;98:2518–2525
  131. Kulkarni S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Research. 2000;60:3592–3598
  132. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood. 2001;97:3910–3918
  133. Abe A, Emi N, Tanimoto M, et al. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood. 1997;90:4271–4277
  134. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31–35: role of the platelet-derived growth factor receptor beta. Acta Haematologica. 2002;107:113–122
  135. Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. British Journal of Haematology. 2003;120:251–256
  136. Granjo E, Lima M, Lopes JM, et al. Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report. Acta Haematologica. 2002;107:108–112
  137. Gupta R, Knight CL, Bain BJ. Receptor tyrosine kinase mutations in myeloid neoplasms. British Journal of Haematology. 2002;117:489–508
  138. Grand FH, Burgstaller S, Kuhr T, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Research. 2004;64:7216–7219
  139. Carroll M, Tomasson MH, Barker GF, et al. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proceedings of the National Academy of Sciences of the USA. 1996;93:14845–14850
  140. Ross TS, Gilliland DG. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. The Journal of Biological Chemistry. 1999;274:22328–22336
  141. Wilbanks AM, Mahajan S, Frank DA, et al. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Experimental Hematology. 2000;28:584–593
  142. Meyer J, Laker C, Janzir N, et al. Activation of the gene for the PDGF receptor beta1 (PDGFRbeta) in interleukin-3-dependent myeloid cells by retroviral insertional mutagenesis: implications for the transforming potential of PDGFRbeta. Growth Factors. 2002;20:131–140
  143. Tomasson MH, Williams IR, Hasserjian R, et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 1999;93:1707–1714
  144. Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Experimental Hematology. 2000;28:140–147
  145. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics. 1996;12:312–314
  146. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222–3225
  147. Pignon JM, Giraudier S, Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. British Journal of Haematology. 1997;96:374–376
  148. Pardanani A, Reeder TL, Kimlinger TK, et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leukemia Research. 2003;27:739–742
  149. Buttner C, Henz BM, Welker P, et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. The Journal of Investigative Dermatology. 1998;111:1227–1231
  150. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of Sciences of the USA. 1995;92:10560–10564
  151. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. The Journal of Clinical Investigation. 1993;92:1736–1744
  152. Kitayama H, Tsujimura T, Matsumura I, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood. 1996;88:995–1004
  153. Ma Y, Carter E, Wang X, et al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. The Journal of Investigative Dermatology. 2000;114:392–394
  154. Ferrao PT, Gonda TJ, Ashman LK. Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leukemia Research. 2003;27:547–555
  155. Chian R, Young S, Danilkovitch-Miagkova A, et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood. 2001;98:1365–1373
  156. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001;97:3559–3567
  157. Hashimoto K, Matsumura I, Tsujimura T, et al. Necessity of tyrosine 719 and phosphatidylinositol 3′-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood. 2003;101:1094–1102
  158. Shivakrupa R, Bernstein A, Watring N, Linnekin D. Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Research. 2003;63:4412–4419
  159. Jelacic T, Linnekin D. PKC{delta} plays opposite roles in growth mediated by wild-type kit and an oncogenic kit mutant. Blood. 2004;
  160. Piao X, Paulson R, van der Geer P, et al. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proceedings of the National Academy of Sciences of the USA. 1996;93:14665–14669
  161. Tanaka A, Konno M, Muto S, et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2004;
  162. Longley BJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the USA. 1999;96:1609–1614
  163. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741–1744
  164. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22:660–664
  165. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Experimental Hematology. 2003;31:686–692
  166. Aguiar RC, Chase A, Coulthard S, et al. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood. 1997;90:3130–3135
  167. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematologica. 2002;107:101–107
  168. Fioretos T, Panagopoulos I, Lassen C, et al. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes, Chromosomes & Cancer. 2001;32:302–310
  169. Guasch G, Popovici C, Mugneret F, et al. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood. 2003;101:286–288
  170. Sohal J, Chase A, Mould S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes, Chromosomes & Cancer. 2001;32:155–163
  171. Still IH, Chernova O, Hurd D, et al. Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 1997;90:3136–3141
  172. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genetics. 1998;18:84–87
  173. Smedley D, Somers G, Venter D, et al. Characterization of a t(8;13)(p11;q11–12) in an atypical myeloproliferative disorder. Genes, Chromosomes & Cancer. 1998;21:70–73
  174. Chaffanet M, Popovici C, Leroux D, et al. t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11–12. Oncogene. 1998;16:945–949
  175. Smedley D, Hamoudi R, Clark J, et al. The t(8;13)(p11;q11–12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Human Molecular Genetics. 1998;7:637–642
  176. Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proceedings of the National Academy of Sciences of the USA. 1998;95:5712–5717
  177. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 1998;92:1735–1742
  178. Kulkarni S, Reiter A, Smedley D, et al. The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. Genomics. 1999;55:118–121
  179. Rosati R, La Starza R, Veronese A, et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood. 2002;99:3857–3860
  180. Aguiar RC, Macdonald D, Mason PJ, et al. Myeloproliferative disorder associated with 8p11 translocations. Blood. 1995;86:834–835
  181. Nakayama H, Inamitsu T, Ohga S, et al. Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder?. British Journal of Haematology. 1996;92:692–695
  182. van den Berg H, Kroes W, van der Schoot CE, et al. A young child with acquired t(8;9)(p11;q34): additional proof that 8p11 is involved in mixed myeloid/T lymphoid malignancies. Leukemia. 1996;10:1252–1253
  183. Belloni E, Trubia M, Gasparini P, et al. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes, Chromosomes & Cancer. 2005;42:320–325
  184. Popovici C, Zhang B, Gregoire MJ, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood. 1999;93:1381–1389
  185. Vizmanos JL, Hernandez R, Vidal MJ, et al. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. The Hematology Journal. 2004;5:534–537
  186. Grand EK, Grand FH, Chase AJ, et al. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes, Chromosomes & Cancer. 2004;40:78–83
  187. Roumiantsev S, Krause DS, Neumann CA, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5:287–298
  188. Chen J, DeAngelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proceedings of the National Academy of Sciences of the USA. 2004;101:14479–14484
  189. Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98:3778–3783
  190. Elliott MA, Hanson CA, Dewald GW, et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–317
  191. Bohm J, Schaefer HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. Journal of Clinical Pathology. 2002;55:862–864
  192. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88:2410–2414
  193. Bohm J, Kock S, Schaefer HE, Fisch P. Evidence of clonality in chronic neutrophilic leukaemia. Journal of Clinical Pathology. 2003;56:292–295
  194. Yanagisawa K, Ohminami H, Sato M, et al. Neoplastic involvement of granulocytic lineage, not granulocytic–monocytic, monocytic, or erythrocytic lineage, in a patient with chronic neutrophilic leukemia. American Journal of Hematology. 1998;57:221–224
  195. Choi IK, Kim BS, Lee KA, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. American Journal of Hematology. 2004;77:366–369
  196. Oliver JW, Deol I, Morgan DL, Tonk VS. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genetics and Cytogenetics. 1998;107:111–117
  197. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1–27
  198. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Annals of Internal Medicine. 1982;97:78–92
  199. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651–1657
  200. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. British Journal of Haematology. 2000;109:540–548
  201. Raghavachar A, Fleischer S, Frickhofen N, et al. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. Journal of Immunology. 1987;139:3753–3758
  202. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. British Journal of Haematology. 1976;33:451–458
  203. Breccia M, Latagliata R, Mengarelli A, et al. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. Haematologica. 2004;89:866–868
  204. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Current Hematology Reports. 2004;3:218–226
  205. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–849
  206. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genetics and Cytogenetics 1986;21:11–30.
  207. Magnusson MK, Meade KE, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002;100:1088–1091
  208. Gunby RH, Cazzaniga G, Tassi E, et al. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica. 2003;88:408–415
  209. Cuneo A, Tomasi P, Ferrari L, et al. Cytogenetic analysis of different cellular populations in chronic myelomonocytic leukemia. Cancer Genetics and Cytogenetics. 1989;37:29–37
  210. Shimada H, Mori T, Shimasaki N, et al. Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia. Leukemia. 2004;18:1142–1144
  211. Cooper LJ, Shannon KM, Loken MR, et al. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood. 2000;96:2310–2313
  212. Nakazawa T, Koike K, Agematsu K, et al. Cytogenetic clonality analysis in monosomy 7 associated with juvenile myelomonocytic leukemia: clonality in B and NK cells, but not in T cells. Leukemia Research. 1998;22:887–892
  213. Emanuel PD. Juvenile myelomonocytic leukemia. Current Hematology Reports. 2004;3:203–209
  214. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics. 2003;34:148–150
  215. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92:267–272
  216. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103:2325–2331
  217. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nature Genetics. 1996;12:137–143
  218. Gitler AD, Kong Y, Choi JK, et al. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. Pediatric Research. 2004;55:581–584
  219. Emanuel PD, Snyder RC, Wiley T, et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood. 2000;95:639–645
  220. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410–419
  221. Korthof ET, Snijder PP, de Graaff AA, et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplantation. 2005;
  222. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clinic Proceedings. 2002;77:1169–1175
  223. Miranda RN, Esparza AR, Sambandam S, Medeiros LJ. Systemic mast cell disease presenting with peripheral blood eosinophilia. Human Pathology. 1994;25:727–730
  224. Baek JY, Tefferi A, Pardanani A, Li CY. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leukemia Research. 2002;26:83–90
  225. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leukemia Research. 2001;25:543–551
  226. Pardanani A, Kimlinger TK, Reeder TL, et al. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. British Journal of Haematology. 2003;120:691–694
  227. Del Canizo MC, Brufau A, Mota A, et al. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica. 1998;83:3–7
  228. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. Journal of Clinical Oncology. 2001;19:2915–2926
  229. Aurich J, Duchayne E, Huguet-Rigal F, et al. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias. Hematology and Cell Therapy. 1998;40:149–158
  230. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;
  231. Bagg A. Role of molecular studies in the classification of lymphoma. Expert Review of Molecular Diagnostics. 2004;4:83–97
  232. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup. Journal of Clinical Oncology. 2004;22:3741–3750

PII: S1521-6926(05)00089-7

doi: 10.1016/j.beha.2005.07.001

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 365-385 , September 2006

Article Tools